Latest Administration News

Global Health Limited reported a robust June quarter with a 65% rise in annual sales and a strategic pivot towards AI-driven efficiencies, aiming for profitability by mid-2026.

Radiopharm Theranostics has received FDA clearance to begin a Phase I clinical trial for RV-01, a novel radiopharmaceutical targeting the 4Ig isoform of B7-H3 in solid tumors, marking a significant step forward in cancer treatment innovation.

Megado Minerals has completed the acquisition of an 80% stake in the Iberian Copper Project in Northern Spain, backed by overwhelming shareholder support. The company is advancing geological mapping and preparing for drilling later this year, while also raising A$780,000 through an institutional placement.

Invictus Energy is preparing to drill the high-impact Musuma-1 exploration well outside its Mukuyu discovery area, while securing National Project Status for its Cabora Bassa Project in Zimbabwe.

Bod Science Limited reports a dramatic reduction in half-year losses alongside revenue growth driven by a strategic shift to THC products. The company remains under a Deed of Company Arrangement with key corporate actions pending shareholder approval.

Lifestyle Communities faces a pivotal VCAT ruling that voids a key deferred management fee clause, prompting an appeal and interim stay that allows fee collection to continue amid legal uncertainty.

Multistack International has announced the discontinuation of its current business operations following a significant asset sale that settled a $3.55 million loan, signaling a major strategic shift for the company.

Multistack International Limited reported a net cash outflow for the quarter ending June 2025 but has strengthened its balance sheet through major loan repayments and is progressing acquisition discussions with SuperLink.

Cycliq Group Ltd reported a 7% increase in customer receipts to $4.8 million for FY2025, alongside a positive net operating cash inflow, driven by strong Q4 sales and new digital initiatives.

Openn Negotiation Ltd has successfully exited voluntary administration following creditor approval of a recapitalisation plan, supported by an interest-free loan from its major shareholder. Despite no substantive business activity this quarter, the company now has over two quarters of funding runway.

Nelson Resources reports promising high-grade gold assay results from rock chip samples at its Yarri tenements, revealing new exploration targets and confirming mineralisation beyond known zones.

Neurizon Therapeutics has formally responded to the FDA's clinical hold on its lead ALS drug NUZ-001, submitting new animal safety data. The company aims to join the HEALEY ALS Platform Trial by late 2025, pending regulatory approval.